<DOC>
	<DOCNO>NCT03001804</DOCNO>
	<brief_summary>The aim non-interventional study collect primarily percentage patient receive full dose dexamethasone ( 40 mg orally daily day 1 , 8 , 15 22 repetitive 28-day cycle , 20 mg &gt; 75 year old patient ) register indication practice condition .</brief_summary>
	<brief_title>Use Lenalidomide ( Revlimid® ) Combination With Dexamethasone Clinical Practice Treatment Newly Diagnosed Multiple Myeloma ( MM ) Transplant Ineligible Patients</brief_title>
	<detailed_description>Multiple myeloma still persistent life-threatening blood cancer characterise tumour proliferation suppression immune system . It rare incurable disease . On average , multiple myeloma diagnose people 65-74 year age , majority newly diagnose patient may eligible aggressive treatment option high-dose chemotherapy stem cell transplant . In February 2015 REVLIMID® ( lenalidomide ) approve combination dexamethasone treatment adult patient previously untreated multiple myeloma eligible transplant . Looking detail combination lenalidomide dexamethasone , role especially adequate effective dosage dexamethasone long term use lenalidomide clearly define well characterise It therefore great relevance gain insight clinical practice routine dexamethasone management dose long term use Revlimid .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Signed Informed Consent Age ≥ 18 year Newly diagnose Multiple Myeloma Not suitable stem cell transplantation Appropriate method contraception accord Risk Minimization Program ( RMP ) Adequate thrombosis prophylaxis Pregnant lactating females No formal exclusion criterion accord recent European Summary Product Characteristics ( SmPC )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Revlimid</keyword>
	<keyword>Lenalidomide</keyword>
	<keyword>Non-transplantable</keyword>
</DOC>